# Market Mayhem: Splits, Stocks, and Surprises!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-09-28T14:01:00.638Z
Source: https://newsyai.com/edition/616a6c10-d580-4e4d-934b-860d93f7ab80
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Market Mayhem: Reverse-Split Roulette 28.9 – DLXY’s Oil Slick, FBGL’s Green Gimmick & CDT’s Biotech Boner (September 28, 2026 Edition!)**

Futures mixed (Dow flatter than a microcap’s post-split float, Nasdaq still hopped up on AI/chip dreams like it’s 2025 on repeat, crude oil snoring through the volatility). Yesterday’s CTNT/DCX/GMEX nuclear-ratio circus is yesterday’s news—those bombs are trading post-split. Fresh compliance meat landing today/soon: **DLXY** (1-for-5 oil trader), **FBGL** (1-for-10 green builder), and **CDT** (1-for-25 AI-biotech asset flipper). Bulls chant “float crush + narrative squeeze = degen rip,” bears sniff the usual dilution bonfire and delisting ghosts.[[1]](https://www.stocktitan.net/news/stock-split-calendar)[[2]](https://www.globenewswire.com/news-release/2026/09/18/3364657/0/en/delixy-holdings-limited-announces-1-for-5-reverse-share-split-effective-september-28-2026.html)

### 1) DLXY (Delixy Holdings Limited): “1-for-5 Crude Boner vs. Trading Desk Burn & Compliance Cancer”

**Why it’s loud**  
1-for-5 reverse split effective Sep 28 for Nasdaq bid-price compliance. Singapore-based wholesaler trading crude oil and oil-based products (fuel oils, gasoline, asphalt, petrochemicals) across Southeast/East Asia and the Middle East. Core crude focus with financing/credit plays—classic energy trader in a volatile commodity world.[[3]](https://stockanalysis.com/stocks/dlxy/company/)[[4]](https://www.globenewswire.com/news-release/2026/04/21/3277892/0/en/delixy-holdings-limited-issues-2026-chairman-s-letter-to-shareholders.html)

**Bull case (float apocalypse + energy sympathy squeeze)**  
Ratio vaporizes shares; any crude price spike, regional demand surge, or LNG expansion chatter could spark a quick degen moonshot. Legit trading ops in high-growth Asian markets—“cleaner register, commodity lottery optics” for the brave.

**Bear case (chronic burn & dilution dragon)**  
Repeated compliance theater plus typical microcap trading risks (margin squeezes, counterparty defaults, oil volatility) scream dilution machine. Thin liquidity, geopolitical/energy execution hurdles, and giant-ratio splits = desperate optics over real margins. High risk of immediate fade.

**My take, first principles (real trading signal vs. listing cancer)**  
Oil trading is a real business with regional moats, but the split signals ongoing listing pressure, not a breakthrough in volumes or margins. Trade the event + any catalyst for volatility only—size tiny, long-term odds brutal without sustained crude strength. **$0.40–3.50** range, **$1.20C** post-split hype — **P$0.40** dilution fade.

### 2) FBGL (FBS Global Limited): “1-for-10 Green Fit-Out Stiffy vs. Construction Cycle & Compliance Limbo”

**Why it’s loud**  
1-for-10 reverse split for Nasdaq compliance. Singapore-based green building contractor specializing in interior fit-outs, mechanical/electrical services, ceilings/partitions, precast components, and sustainable construction for institutional, residential, commercial, and industrial projects. ESG-adjacent narrative in a cyclical sector.[[5]](https://stockanalysis.com/stocks/fbgl/company/)[[6]](https://www.renaissancecapital.com/Profile/FBGL/FBS-Global/IPO)

**Bull case (float compression + green building hype)**  
Extreme ratio crushes shares; any infrastructure/green mandates, project wins, or sustainable construction tailwinds could fuel a quick pop. Legit track record in Singapore’s building boom—“cleaner register, ESG optics” for the degen crowd.

**Bear case (cash burn & dilution bonfire)**  
Serial compliance scrambles plus typical construction risks (project delays, cost overruns, cyclical demand) scream the same old story. Thin trading, execution hurdles in competitive fit-out space, and history of dilution = fade after the pop.

**My take, first principles (real construction signal vs. microcap cancer)**  
Green building has real demand tailwinds, but the split is pure survival theater over near-term profitability or backlog strength. Trade the event + any news catalysts carefully, not the long-term ESG tale. **$0.20–2.80** range, **$1.00C** green pump — **P$0.20** dilution fade.

### 3) CDT (CDT Equity Inc., formerly Conduit Pharmaceuticals): “1-for-25 AI-Biotech Tease vs. Asset Flip & Dilution Dragon”

**Why it’s loud**  
1-for-25 reverse split for compliance. Data-driven biopharma play focused on identifying/enhancing clinical-stage assets via AI, solid-form chemistry, and partnerships (autoimmune, diabetes, infertility, oncology, etc.). Repositioning model with potential IP extensions—classic microcap biotech with a tech twist.[[7]](https://www.cdtequity.com/corporate-profile/about-us/)[[8]](https://stockanalysis.com/stocks/cdt/company/)

**Bull case (float apocalypse + immuno/AI sympathy squeeze)**  
Nuclear ratio vaporizes shares; any pipeline update, partnership, AI-driven indication win, or sector tailwind could spark a degen moonshot. Legit asset-flip strategy in hot spaces—“cleaner register, lottery optics” for the brave.

**Bear case (chronic burn & dilution dragon)**  
Extreme split plus typical early-stage biotech losses, going-concern flags, and financing needs scream dilution machine. Thin liquidity, clinical execution hurdles, and pattern of giant-ratio splits = desperate optics over fundamentals. High risk of immediate fade.

**My take, first principles (real asset signal vs. listing cancer)**  
AI + solid-form tech has applications for repurposing, but the split signals ongoing listing pressure, not a breakthrough. Trade the event + any catalyst for volatility only—size tiny, long-term odds remain brutal without fresh data or deals. **$0.15–3.00** range, **$1.10C** post-split hype — **P$0.15** dilution fade.

**Tape-Side Tactics (DLXY/FBGL/CDT Degens – September 28 Edition)**  
- **DLXY**: **$0.40–3.50** crude boner; **$1.20C** post-split hype, **P$0.40** dilution fade.  
- **FBGL**: **$0.20–2.80** green stiffy; **$1.00C** fit-out pump, **P$0.20** dilution fade.  
- **CDT**: **$0.15–3.00** AI-biotech tease; **$1.10C** asset flip, **P$0.15** dilution fade.  
- Size small, watch for failed momentum or failed compliance—dilution remains the house edge.

Reverse-split addiction still tightening the noose amid AI hype and micro-madness. Balls-deep DYOR, NFA, degens—duck the dilutions!

**Sources** (for tracking every claim above):  
- Reverse splits & calendars: Stock Titan, GlobeNewswire, TipRanks, company announcements (Sep 2026 data).[[1]](https://www.stocktitan.net/news/stock-split-calendar)[[2]](https://www.globenewswire.com/news-release/2026/09/18/3364657/0/en/delixy-holdings-limited-announces-1-for-5-reverse-share-split-effective-september-28-2026.html)[[9]](https://www.strasmore.com/blog/upcoming-stock-splits)  
- Company overviews & filings: StockAnalysis, Yahoo Finance, SEC/GlobeNewswire releases.[[3]](https://stockanalysis.com/stocks/dlxy/company/)[[5]](https://stockanalysis.com/stocks/fbgl/company/)[[7]](https://www.cdtequity.com/corporate-profile/about-us/)  
- Broader microcap/premarket context & volatility: OTC Markets, Yahoo Finance, Seeking Alpha feeds.  

Balls-deep in the tape—stay frosty!
